Ticker

Alpha Teknova (NASDAQ: TKNO) executives told investors the company delivered faster growth and improved profitability metrics in 2025, and said they believe the business is approaching an "inflection point" as it scales its mix of research-grade and GMP-grade reagents. On the company's fourth-quarter and full-year 2025 earnings call, management highlighted rising clinical customer counts, improving manufacturing

Alpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call Transcript

Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provides 2026 revenue guidance of $42-44 million

HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026,…

Alpha Teknova, Inc. (NASDAQ: TKNO - Get Free Report)'s stock price traded up 2.6% during mid-day trading on Friday. The company traded as high as $3.94 and last traded at $3.90. 142,045 shares were traded during mid-day trading, a decline of 10% from the average session volume of 158,186 shares. The stock had previously closed